#ICYMI Yesterday, we announced a collaboration with @MDAndersonNews that will join MD Anderson’s expertise with our proprietary ACT bacterial #celltherapy platform to develop a novel treatment for individuals with #immunotherapy-resistant #cancer.
A new partnership between MD Anderson Cancer Center and a California-based biotech company aims to overcome some of the challenges of certain cancer treatments. https://t.co/nsuYXIrLxM
Today, we announced a collaboration with @MDAndersonNews to develop a novel #microbiome treatment for individuals with immunotherapy-resistant #cancer.
Read today’s press release at https://t.co/pfEyAroHpi.
Today, we administered the first dose of our investigational bacterial cell therapy, FB-001. This Phase 1 #clinicaltrial will evaluate the safety, efficacy and engraftment of FB-001 in the treatment of enteric #hyperoxaluria, a serious metabolic disorder.
https://t.co/7Ubw3Viu0l
Thanks to @Venrock for featuring @FederationBio CEO Emily Drabant Conley on the #RunningThroughWalls podcast! Tune in to hear @edrabantconley discuss leadership lessons from her time at 23andMe and how Federation Bio is disrupting the #microbiome space: https://t.co/VdHkdvA3OF
An emerging scientific understanding of the human #microbiome is transforming our relationship with microbes – elevating them from menace to medicine as our understanding of their profound role in human physiology has come into focus. Learn more at https://t.co/KfQ5ZWKYdl
Emerging scientific understanding of the human #microbiome has demonstrated the profound role that microbes play in human physiology and rapidly elevated their therapeutic potential. Learn more about our novel approach at https://t.co/KfQ5ZWKYdl
We’re pioneering new approaches for treating intractable diseases by combining an unprecedented number of #microbial strains into highly diverse consortia, in some instances optimized with genetically engineered bacteria to enhance the immune system. https://t.co/KfQ5ZWKYdl
We’re pleased to announce that Federation Bio has come out of stealth mode with a $50 million Series A financing, two novel #microbial therapeutic platforms and an exceptional leadership team. Watch to see what we do next! Read the press release here: https://t.co/9cdJvhUzSQ